{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:54:30Z","timestamp":1761008070313,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.vascn.2016.07.002","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T07:05:44Z","timestamp":1468739144000},"page":"62-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat"],"prefix":"10.1016","volume":"82","author":[{"given":"Patricia N.","family":"Banfor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A.","family":"Gintant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Lipari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip D.","family":"Zocharski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2016.07.002_bb0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-3565(24)38170-4","article-title":"Plasma levels of enalaprilat in chronic therapy of heart failure: Relationship to adverse events","volume":"289","author":"Brunner-La Rocca","year":"1999","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/j.vascn.2016.07.002_bb1000","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/10915819309141598","article-title":"Final Report on the safety assessment of polyethylene glycols (PEGs) -6, -8, -32, -75, -150, -14M, -20M","volume":"12","author":"Cosmetic Ingredient Review Expert Panel","year":"1993","journal-title":"Journal of the American College of Toxicology"},{"issue":"6","key":"10.1016\/j.vascn.2016.07.002_bb0010","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/10915819409141005","article-title":"Final report on the safety assessment of propylene glycol and polypropylene glycols","volume":"13","author":"Panel","year":"1994","journal-title":"Journal of the American College of Toxicology"},{"issue":"12","key":"10.1016\/j.vascn.2016.07.002_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052985","article-title":"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P\u2081) and hypertension (S1P\u2083) in rat","volume":"7","author":"Fryer","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vascn.2016.07.002_bb0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/10915810600961531","article-title":"Nonclinical vehicle use in studies by multiple routes in multiple species","volume":"6","author":"Gad","year":"2006","journal-title":"International Journal of Toxicology"},{"issue":"2","key":"10.1016\/j.vascn.2016.07.002_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1091581815622442","article-title":"Tolerable levels of nonclinical vehicles and formulations used in studies by multiple routes in multiple species with notes on methods to improve utility","volume":"35","author":"Gad","year":"2016","journal-title":"International Journal of Toxicology"},{"issue":"2","key":"10.1016\/j.vascn.2016.07.002_bb0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/clpt.1984.159","article-title":"Therapeutic and metabolic effects of sotalol","volume":"36","author":"Holmberg","year":"1984","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1\u20132","key":"10.1016\/j.vascn.2016.07.002_bb0035","first-page":"111","article-title":"An intravenous formulation decision tree for discovery compound formulation development","volume":"253","author":"Lee","year":"2002","journal-title":"International Journal of Pharmaceutics"},{"issue":"5","key":"10.1016\/j.vascn.2016.07.002_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF00636787","article-title":"Time-course of the anti-hypertensive action of atenolol: Comparison of response to first dose and to maintained oral administration","volume":"18","author":"Leonetti","year":"1980","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1\u20132","key":"10.1016\/j.vascn.2016.07.002_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.05.049","article-title":"Developing early formulations: Practice and perspective","volume":"341","author":"Li","year":"2007","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.vascn.2016.07.002_bb0055","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.bmcl.2006.10.013","article-title":"Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: Implication for targeting protein kinases in metabolic diseases","volume":"17","author":"Liu","year":"2007","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"4","key":"10.1016\/j.vascn.2016.07.002_bb0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cbpa.2005.05.003","article-title":"Predictive, non-GLP models of secondary pharmacodynamics: Putting the best compounds forward","volume":"9","author":"Reinhart","year":"2005","journal-title":"Current Opinion in Chemical Biology"},{"year":"1984","series-title":"Solubilization of some poorly soluble drugs by cosolvents (formulation, ideality, polarity)","author":"Rubino","key":"10.1016\/j.vascn.2016.07.002_bb0065"},{"issue":"3","key":"10.1016\/j.vascn.2016.07.002_bb0070","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bcp.2011.10.019","article-title":"A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats","volume":"83","author":"Scott","year":"2012","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2016.07.002_bb0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.107.132530","volume":"325","author":"Segreti","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2016.07.002_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00498254.2013.845706","article-title":"Solvent-based formulations for intravenous mouse pharmacokinetic studies: Tolerability and recommended solvent dose limits","volume":"44","author":"Thackaberry","year":"2014","journal-title":"Xenobiotica"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871916300764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871916300764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:05Z","timestamp":1761004805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871916300764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":16,"alternative-id":["S1056871916300764"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2016.07.002","relation":{},"ISSN":["1056-8719"],"issn-type":[{"type":"print","value":"1056-8719"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2016.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}